FTC raises concern about Novo Nordisk attempt to acquire obesity startup Metsera

Taking stock of the drug industry, from the lab to the medicine chest

November 5, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FTC raises concern about Novo Nordisk attempt to acquire obesity startup Metsera An agency official says the structure of the Novo Nordisk offer for Metsera, an obesity startup, may violate U.S. law. By Elaine Chen and Ed Silverman STAT+ | Novo CEO, in bidding war with Pfizer, says Metsera's drugs would complement pipeline The company, facing off in a bidding war with Pfizer for Metsera, is aiming to regain its footing in the obesity drug market. By Andrew Joseph STAT+ | Recursion CEO Chris Gibson out as company head after 12 years He will be replaced by current R&D head and Chief Commercial Officer Najat Khan as the techbio positions itself for next phase of AI drug discovery. By Brittany Trang Adobe STAT+ | Investors back new biotech with heart disease treatment from China  The new biotech raised $185 million to run a global late stage trial of a hypertrophic cardiomyopathy medicine. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser